Middle East & Africa Uterine Cancer Therapeutics & Diagnostics Market - Growth, Trends, COVID-19 Impact, and Forecasts (2022 - 2027)

Market Overview

The Middle East & Africa Uterine Cancer Therapeutics & Diagnostics Market is expected to grow with a CAGR of 5.7% during the forecasted period. The key factors propelling the growth of this market are rise in awareness about uterine diseases and their available therapies, increasing health care expenditure in drug development, and subsequent technological advancements.

In South Africa, the Cancer Association of South Africa (CANSA) is an organization that offers integrated services to the people affected by cancer in the country. Its mission involves providing research with regards to lowering cancer risk, educating the public regarding symptoms, screening and risk reduction, and providing care and support to all those affected by cancer. Furthermore, the department of Health in South Africa implemented programs to improve the health of women, all these programs is expected to increase early diagnosis procedures in near future.

As per National Clinical Trials (NCT) Registry, as of June 18, 2020, in Saudi Arabia "ASPIRE" clinical trial which is under phase II development for the treatment of endometrial cancer with stereotactic ablative radiation (SABR/SBRT) therapy. In near future, if trial shows positive outcome then it will boost the market as new therapy can be expected in coming years.

Therefore, these initiatives and research efforts are expected to boost the market in the region, in future.

Scope of the report

As per the scope of the report, uterine cancer is a common form of cancer of the female reproductive system that initiates in the lining of the uterus. The market is segmented by type of cancer, therapeutics, diagnostics and geography.

Report scope can be customized per your requirements. Click here.

Key Market Trends

Endometrial Adenocarcinoma Segment is Expected to Witness Highest Growth Over the Forecast Period

Growing burden of endometrial adenocarcinoma is expected to drive the Uterine Cancer Therapeutics & Diagnostics Market in this segment.

Increasing obesity among women is considered as the prime factor responsible for the growing incidence of the endometrium carcinoma. with the growing incidence of the disease and the rising awareness about the same, it is believed that rapid growth of the segment will occur in the coming future.

Furthermore, endometrial cancer often produces symptoms at relatively early stages, so the disease is generally diagnosed early this factor drives the market in coming years because diagnostic procedures will increase for the early diagnosis of endometrial cancer.

As per National Clinical Trials (NCT) Registry, as of June 18, 2020, in Israel, South Africa and other countries Merck Sharp & Dohme Corp is conducting phase II clinical trial ((MK-3475-158/KEYNOTE-158) for endometrial carcinoma with pembrolizumab (MK-3475). In near future, if trial shows positive outcome then it will boost the market as new therapy for endometrial cancer can be expected in coming years.

Thus, owing to above factors the marketis expected to show growth in near future.

To understand key trends, Download Sample Report